JUNIPERA: Secukinumab reduces flare risk in juvenile PsA, enthesitis-related arthritis – Healio
Supply/Disclosures
Revealed by:
Supply:
Brunner H. Abstract 1424. Launched at: ACR Convergence 2021; November 5-9, 2021 (digital meeting).
…….
Supply/Disclosures
Revealed by:
Supply:
Brunner H. Abstract 1424. Launched at: ACR Convergence 2021; November 5-9, 2021 (digital meeting).
Disclosures:
Brunner reviews consulting costs from Aurinia, AbbVie, AstraZeneca-Medimmune, Biogen, Boehringer, Bristol-Myers Squibb, Celgene, Eli Lilly & Co., EMD Serono, GlaxoSmithKline, F. Hoffmann-La Roche, Merck, Novartis, R-Pharm, Sanofi and Pfizer; grant/evaluation assist from Bristol-Myers Squibb, Eli Lilly & Co., GlaxoSmithKline, F. Hoffmann-La Roche, Janssen, Novartis and Pfizer; and talking costs from Pfizer, Roche and GlaxoSmithKline. Please see the research for all completely different authors’ related monetary disclosures.
We have been unable to course of your request. Please try as quickly as extra later. Do You’d like to proceed to have this problem please contact [email protected].
Hermine Brunner
Secukinumab is efficacious in youngsters and adolescents with psoriatic arthritis and enthesitis-associated arthritis, Ensuing in a significantly longer time to flare versus placebo, Based mostly on knowledge currented at ACR Convergence 2021.
“Enthesitis-associated arthritis, or Period, and juvenile psoriatic arthritis, or JPsA, are two JIA packages that recurrent the pediatric counterparts of grownup non-radiographic axial spondyloarthritis and grownup psoriatic arthritis, respectively,” Hermine Brunner, MD, MSc, MBA, of the College of Cincinnati and Cincinnati Kid’s Hospital Medical Center, informed attendees On the digital meeting. “Secukinumab is a monoclonal antibody concentrating on interleukin-17A and has been found efficient And guarded in use Inside these grownup Sorts of arthritis.”
“In youngsters and adolescents with Period or JPsA, secukinumab demonstrated a significantly longer time to flare, and fewer Quantity of flares, in contrast with placebo,” Hermine Brunner, MD, MSc, MBA, informed attendees. Supply: Adobe Inventory
To look at the efficacy And guardedty of secukinumab (Cosentyx, Novartis) in lively enthesitis-associated arthritis and juvenile PsA, Brunner and colleagues carried out the randomized, double-blind, placebo-managed JUNIPPeriod trial. Sufferers aged 2 to youthful than 18 yrs with A minimal of 6 months’ interval of both situation, and lively illness, have been enrolled. The two-yr research started with an open-label remedy interval, By which participant acquired subcutaneous secukinumab — both 75 mg or 150 mg Counting on weight — at baseline and weeks 1, 2, 3, 4, 8 and 12.
People who achieved A minimal of JIA ACR30 response at week 12 have been then randomized into double-blind interval, By which they both proceedd with secukinumab or acquired a placebo every 4 weeks till they expert illness flare or week 100. The primary endpoint was the time to flare By way of the double-blind interval. Key secondary endpoints included JIA ACR30/50/70/90/100, inlively illness, juvenile arthritis illness exercise rating (JADAS), enthesitis, lively joint counts And guardedty.
Analyses included the proportion of affected individuals with illness flare, …….
